問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

張定宗Chang, Ting-Tsung
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

  • ttchang@mail.ncku.edu.tw

Recruiting Trial

28Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張定宗

List

88Cases

2008-05-01 - 2011-08-15

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-12-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2009-08-01 - 2012-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2009-05-01 - 2011-04-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2009-08-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-11-01 - 2012-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2012-11-01 - 2014-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-08-01 - 2014-06-30

Phase III

A phase 3 study with Asunaprevir and Daclatasvir (DUAL) for Null or Partial Responders to Peginterferon Alfa and Ribavirin(P/R), Intolerant or Ineligible to P/R Subjects and Treatment –Naïve Subjects with Chronic Hepatitis C Genotype 1b Infection

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    Asunaprevir (BMS-650032)、Daclatasvir (BMS-790052)

Participate Sites
8Sites

Terminated8Sites

2012-10-01 - 2015-04-30

Phase II

An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C

  • Condition/Disease

    Hepatitis C virus

  • Test Drug

    BMS-650032 Asunaprevir / BMS-790052 Daclatasvir

Participate Sites
8Sites

Terminated8Sites

2014-07-01 - 2018-08-31

Others

A Long-Term Follow-Up Study of Subjects Who Participated in a Clinical Trial in which Peginterferon Lambda-1a (BMS-914143) was Administered for the Treatment of Chronic Hepatitis C

  • Condition/Disease

    Chronic Hepatitis C

  • Test Drug

    NA

Participate Sites
2Sites

Terminated1Sites

Study ended1Sites

1 5 6 7 8 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB